Drug
MM-151
MM-151 is a pharmaceutical drug with 3 clinical trials. Historical success rate of 50.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
50.0%
Based on 1 completed trials
Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(33%)
Phase Distribution
Ph phase_1
3
100%
Phase Distribution
3
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
3(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
33.3%
1 of 3 finished
Non-Completion Rate
66.7%
2 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(1)
Terminated(2)
Detailed Status
Terminated1
Completed1
Withdrawn1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
50.0%
Most Advanced
Phase 1
Trials by Phase
Phase 13 (100.0%)
Trials by Status
terminated133%
completed133%
withdrawn133%
Recent Activity
0 active trials
Showing 3 of 3
completedphase_1
Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment
NCT01520389
terminatedphase_1
Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib
NCT02538627
withdrawnphase_1
Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer
NCT02785068
Clinical Trials (3)
Showing 3 of 3 trials
NCT01520389Phase 1
Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment
NCT02538627Phase 1
Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib
NCT02785068Phase 1
Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3